Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 174
- Registration Number
- NCT00446225
- Locations
- 🇫🇷
Centre Hospitalier René Dubos, Cergy Pontoise, France
🇫🇷Centre Hospitalier Du Mans, Le Mans, France
🇫🇷Centre Oscar Lambret, Lille, France
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
- Conditions
- LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00439361
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00434252
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00434226
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT00434642
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University College, London
- Target Recruit Count
- 846
- Registration Number
- NCT00433498
- Locations
- 🇬🇧
Walsall Manor Hospital, Walsall, England, United Kingdom
🇬🇧Weston General Hospital, Weston-super-Mare, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 189
- Registration Number
- NCT00432172
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸Centro Oncológico Regional de Galicia, A Coruña, Spain
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- Conditions
- Childhood Germ Cell TumorOvarian CancerTeratoma
- Interventions
- Drug: carboplatinDrug: etoposideDrug: ifosfamideDrug: paclitaxelDrug: thiotepaProcedure: autologous hematopoietic stem cell transplantationDrug: MesnaBiological: filgrastim
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 39
- Registration Number
- NCT00431704
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 38
- Registration Number
- NCT00431613
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷IASO General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.